Vial's INHBE siRNA is a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE and its gene product, Activin E -- Leading key opinion leaders (KOL ...
SAN FRANCISCO, May 25, 2023 /PRNewswire/ -- Vial, a global tech-first CRO providing next-generation clinical trial management services, announced it will be a sponsor and exhibitor at the 2023 BIO ...
Nov 18 (Reuters) - Provention Bio Inc said on Friday its recently approved diabetes drug, teplizumab, would cost $13,850 a vial. The U.S. Food and Drug Administration approved use of the drug, to be ...
Nov 18 (Reuters) - Provention Bio Inc PRVB.O said on Friday its recently approved diabetes drug, teplizumab, would cost $13,850 a vial. The U.S. Food and Drug Administration approved use of the drug, ...
Nov 18 (Reuters) - Provention Bio Inc said on Friday that its recently approved diabetes drug, teplizumab, would cost $13,850 per vial. The U.S. Food and Drug Administration approved use of the drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback